Feb 23, 2026 by Reuben Gregg BrewerIs Medical Properties Trust Stock Going to $0?Medical Properties Trust is working on a turnaround, and results are starting to improve.
Feb 23, 2026 by Rich SmithWhy Eli Lilly Stock Just PoppedEli Lilly has some good news for investors today. Novo Nordisk has some bad news (which is also good news for Lilly).
Feb 23, 2026 by Leo SunWhere Will Broadcom (AVGO) Be in 5 Years?The chipmaking and software giant has a bright future.
Feb 23, 2026 by Neil PatelCrypto Market Sell-Off: 1 High-Conviction Cryptocurrency to Buy and 1 to AvoidKeeping a steady head is crucial in turbulent market conditions.
Feb 23, 2026 by Jonathan PoncianoFrom Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million BackerAgios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs.
Feb 23, 2026 by Katie BrockmanVEA vs. SPDW: Which International ETF Is the Best Choice for Investors?Explore how differences in holdings, risk, and yield shape the appeal of these two top international ETFs for portfolio builders.
Feb 23, 2026 by Katie BrockmanBetter Global ETF Buy: Can Investors Earn More with IEFA or SPGM?Explore how sector focus, risk profiles, and fund size set these two global ETFs apart for internationally minded investors.
Feb 23, 2026 by Katie BrockmanIEMG vs. VXUS: Which International ETF Is the Better Buy Right Now?Key differences in cost, sector mix, and global reach shape how these ETFs fit into an international diversification strategy.
Feb 23, 2026 by Katie BrockmanBetter Buy: How Small-Cap ETFs ISCG and IJT Compare on Fees, Risk, and IncomeWeighing cost, diversification, and risk, this side-by-side ETF analysis highlights key trade-offs for small-cap growth investors.
Feb 23, 2026 by Katie BrockmanSmall-Cap Showdown: How Vanguard's VB Compares to Schwab's SCHA on Fees, Risk, and DiversificationExplore how key differences in fees, sector focus, and risk profiles set these two small-cap ETFs apart for investors.
Feb 23, 2026 by Rich SmithWhy Novo Nordisk Stock Just CrashedGLP-1 weight loss drug CagriSema may not be the salvation Novo Nordisk was hoping for.
Feb 23, 2026 by Rick OrfordDisney's 2026 Film Slate Could Ignite a Powerful ComebackDisney's 2026 movie slate could unlock billions in box office revenue and force Wall Street to rethink the stock. Is now the time to buy before a rerating?
Feb 23, 2026 by Prosper Junior BakinyEli Lilly: The Weight‑Loss and Diabetes Powerhouse I'd Hold Through Any Market CrashThe stock looks unstoppable.
Feb 23, 2026 by Jonathan PoncianoViridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million StakeViridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments.
Feb 23, 2026 by Jonathan PoncianoSpyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 MillionSpyre Therapeutics develops preclinical monoclonal antibody therapies targeting inflammatory bowel disease and related conditions.
Feb 23, 2026 by Justin Pope2 Unstoppable Growth Stocks to Buy Right Now for $1,000These companies just turned in fourth-quarter earnings reports that should have investors salivating at their upside in 2026 and beyond.
Feb 23, 2026 by James HalleyThis 4.9%-Yield Oil Pipeline Stock Is up 18% in 2026 -- and Still Looks CheapThe midstream oil and gas company has scheduled its fourth-quarter earnings on Feb. 23.
Feb 23, 2026 by Jonathan PoncianoBiotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50%Centessa Pharmaceuticals develops clinical-stage therapies for rare and serious diseases, leveraging a portfolio approach in biopharma.
Feb 23, 2026 by Reuben Gregg Brewer3 High-Yield Energy Stocks to Buy in FebruaryWith yields of up to 6%, these three reliable income generators are still attractive buys as February draws to a close.
Feb 23, 2026 by Jonathan PoncianoBiotech Fund Dumps $84 Million of Nuvalent With Stock Up 29%Nuvalent develops targeted cancer therapies, advancing clinical candidates for patients with limited treatment options in oncology.
